Truist Securities Rates Viridian Therapeutics (VRDN) buy
Truist Securities has reaffirmed its Buy rating for Viridian Therapeutics, setting a price target of $38, a 106.86% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $38 price target on June 30, 2026.
Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).
VRDN
Viridian Therapeutics, Inc.
Key Points
- Truist Securities reiterated its Buy rating on Viridian Therapeutics, Inc. (VRDN) with a target price of $38, while the stock currently trades at $18.37.
- Truist Securities's $38 price target implies 106.86% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
- The stock has a 52-week range of $13.18 to $34.29, indicating potential for growth as it remains below its previous highs.
- Analysts are generally positive on Viridian, with a consensus target price of $36.62 from 16 opinions.
Get $VRDN trade alerts by text
We text you when insiders, Congress or big funds trade $VRDN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures
Truist Securities Maintains Buy Rating
On June 30, 2026, Truist Securities reiterated its Buy rating on Viridian Therapeutics, Inc. (NASDAQ: VRDN) with a target price of $38. The stock was trading at $18.37 on the same day, showing a significant gap between the current price and the target.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Recent Analyst Ratings
Truist's latest rating reflects confidence in Viridian's potential. This is not the only positive sentiment; RBC Capital also maintained an Outperform rating with a target of $38 on the same day. Additionally, Wells Fargo upgraded Viridian to 'Buy' just the day before, setting a price target of $31. These ratings suggest a growing optimism among analysts about the company's future prospects.
How Viridian Therapeutics, Inc. Stock Has Traded
Viridian's stock has been fluctuating within a 52-week range of $13.18 to $34.29. Currently, it trades well below its 200-day moving average of $23.36. This positioning could indicate potential for recovery if the market responds positively to the company's developments.
$VRDN price target
Viridian Therapeutics, Inc. daily closes and this analyst's $38 target. Not advice.
What Viridian Therapeutics, Inc. Does
Viridian Therapeutics specializes in developing treatments for serious and rare diseases. Its focus on IGF-1R therapies, particularly for thyroid eye disease, positions it well in the biotechnology sector. The company is headquartered in Waltham, Massachusetts, and employs about 252 people.
What’s Next for Viridian?
Investors should watch for the company's next earnings report scheduled for November 5, 2026. As a reminder, the ratings from Truist and other analysts reflect past data and may not represent current market conditions. Keeping an eye on further ratings and the upcoming earnings could provide insights into Viridian's trajectory.
Related Filing Alerts
Source: Truist Securities's rating change on $VRDN (Jun 30, 2026). Written by software, not financial advice. How we make alerts